Jan 2022: Pembrolizumab (Keytruda, Merck) has been approved by the Food and Drug Administration for the adjuvant treatment of patients with renal cell carcinoma (RCC) who are at intermediate-high or high risk of recurrence after ..
August 2021: Combinația dintre lenvatinib (Lenvima, Eisai) și pembrolizumab (Keytruda, Merck) a fost aprobată de Food and Drug Administration pentru tratamentul de primă linie al pacienților adulți cu carcinom avansat de celule renale ..
August 2021: Tivozanib (Fotivda, AVEO Pharmaceuticals, Inc.), un inhibitor al kinazei, a fost aprobat de FDA pentru pacienții adulți cu carcinom renal avansat recidivat sau refractar cu celule renale (RCC) după două sau mai multe sistemice anterioare ..
Many patients with kidney cancer do not know why they have this disease, meaning the causes of kidney cancer are relatively unknown. After the examination, they will be very surprised. Some even feel that the kidney is not a probl..